Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
Phase 1
Recruiting
- Conditions
- Recurrent vulvovaginal candidiasisTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]MedDRA version: 20.1Level: PTClassification code: 10047784Term: Vulvovaginal candidiasis Class: 100000004862
- Registration Number
- CTIS2023-507527-28-00
- Lead Sponsor
- immaTech Biologics AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 251
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method